Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease
Cody S. Nelson, Ilona Baraniak, Daniele Lilleri, et al.
The Journal of Infectious Diseases (2019) Vol. 221, Iss. Supplement_1, pp. S45-S59
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine
Xintao Hu, Krithika P. Karthigeyan, Savannah Herbek, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 2, pp. 455-466
Closed Access | Times Cited: 27
Safety and Immunogenicity of a Messenger RNA–Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial
Carlos Fierro, Daniel C. Brune, Marian Shaw, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 3, pp. e668-e678
Open Access | Times Cited: 18
The mRNA-1647 vaccine: A promising step toward the prevention of cytomegalovirus infection (CMV)
Adewunmi Akingbola, Abiodun Adegbesan, Olajumoke Adewole, et al.
Human Vaccines & Immunotherapeutics (2025) Vol. 21, Iss. 1
Open Access | Times Cited: 2
40 Years after the Registration of Acyclovir: Do We Need New Anti-Herpetic Drugs?
Anna Majewska, Beata Młynarczyk-Bonikowska
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3431-3431
Open Access | Times Cited: 67
Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, V160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial
Rituparna Das, Daniel Blázquez‐Gamero, David I. Bernstein, et al.
The Lancet Infectious Diseases (2023) Vol. 23, Iss. 12, pp. 1383-1394
Closed Access | Times Cited: 26
Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization
Cody S. Nelson, Jennifer A. Jenks, Norbert Pardi, et al.
Journal of Virology (2020) Vol. 94, Iss. 9
Open Access | Times Cited: 50
The cytomegalovirus gB/MF59 vaccine candidate induces antibodies against an antigenic domain controlling cell-to-cell spread
Ariane C. Gomes, Ilona Baraniak, Anastasia Lankina, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Characterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults
Kai Wu, Yixuan J. Hou, Dan Makrinos, et al.
Journal of Virology (2024) Vol. 98, Iss. 4
Open Access | Times Cited: 8
Vaccine value profile for cytomegalovirus
Suresh B. Boppana, Michiel van Boven, William J. Britt, et al.
Vaccine (2023) Vol. 41, pp. S53-S75
Open Access | Times Cited: 13
A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial
Leike Li, Daniel C. Freed, Yaping Liu, et al.
npj Vaccines (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 28
Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development
Xintao Hu, Hsuan-Yuan Wang, Claire E. Otero, et al.
Annual Review of Virology (2022) Vol. 9, Iss. 1, pp. 491-520
Open Access | Times Cited: 22
Primary, Secondary, and Tertiary Prevention of Congenital Cytomegalovirus Infection
Pauline Sartori, Charles Egloff, Najeh Hcini, et al.
Viruses (2023) Vol. 15, Iss. 4, pp. 819-819
Open Access | Times Cited: 12
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies.
Eric P. Schultz, Lars Ponsness, Jean-Marc Lanchy, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
The pentameric complex is not required for congenital CMV transmission in seronegative rhesus macaques
Hsuan-Yuan Wang, Husam Taher, Craig N. Kreklywich, et al.
Science Translational Medicine (2025) Vol. 17, Iss. 789
Closed Access
Human cytomegalovirus gH/gL/gO binding to PDGFRα provides a regulatory signal activating the fusion protein gB that can be blocked by neutralizing antibodies
Eric P. Schultz, Lars Ponsness, Jean-Marc Lanchy, et al.
Journal of Virology (2025)
Open Access
Developing a Vaccine Against Human Cytomegalovirus: Identifying and Targeting HCMV’s Immunological Achilles’ Heel
Anastasia Lankina, Marta Brezmes Raposo, Alexander Hargreaves, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 435-435
Open Access
Single-cell analysis of memory B cells from top neutralizers reveals multiple sites of vulnerability within HCMV Trimer and Pentamer
Matthias Zehner, Mira Alt, Artem Ashurov, et al.
Immunity (2023) Vol. 56, Iss. 11, pp. 2602-2620.e10
Open Access | Times Cited: 9
Rationally designed Human Cytomegalovirus gB nanoparticle vaccine with improved immunogenicity
Michela Perotti, Jessica Marcandalli, Davide Demurtas, et al.
PLoS Pathogens (2020) Vol. 16, Iss. 12, pp. e1009169-e1009169
Open Access | Times Cited: 21
Immune Prophylaxis and Therapy for Human Cytomegalovirus Infection
Evi Struble, Haruhiko Murata, Takashi Komatsu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8728-8728
Open Access | Times Cited: 16
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine
Xiaohua Ye, David Shih, Zhiqiang Ku, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 2
The pentameric complex is not required for vertical transmission of cytomegalovirus in seronegative pregnant rhesus macaques
Hsuan-Yuan Wang, Husam Taher, Craig N. Kreklywich, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
EEHV1A glycoprotein B subunit vaccine elicits humoral and cell-mediated immune responses in mice
Jennifer L. Spencer Clinton, Tabitha E. Hoornweg, Jie Tan, et al.
Vaccine (2022) Vol. 40, Iss. 35, pp. 5131-5140
Open Access | Times Cited: 8
Long-Term Evolution of the Adaptive NKG2C+ NK Cell Response to Cytomegalovirus Infection in Kidney Transplantation: An Insight on the Diversity of Host–Pathogen Interaction
Michelle Ataya, Dolores Redondo‐Pachón, Laura Llinàs-Mallol, et al.
The Journal of Immunology (2021) Vol. 207, Iss. 7, pp. 1882-1890
Open Access | Times Cited: 8
HCMV carriage in the elderly diminishes anti-viral functionality of the adaptive immune response resulting in virus replication at peripheral sites
Emma L. Davies, Mahlaqua Noor, Eleanor Y. Lim, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
Can We Prevent Congenital Infection by Cytomegalovirus?
Stanley A. Plotkin
Clinical Infectious Diseases (2023) Vol. 76, Iss. 10, pp. 1705-1707
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top